Regis Resources and Vault Minerals to Merge in $10.7B Gold Deal 
Strategy Reports Q1 Loss as Bitcoin Holdings Trigger $14.46 Billion Unrealized Hit 
Agentic AI Boom to Drive Massive Growth in CPU Market, UBS Says 
Strategy Hints at Bitcoin Sales to Cover Dividends After Massive Q1 Loss 
GameStop Proposes $56 Billion eBay Acquisition in Bold Strategic Move 
Anthropic’s $1.5B AI Venture with Wall Street Firms Targets Private Equity Market 
Hugo Boss Beats Q1 Profit Expectations Despite Market Headwinds 
AMD Q1 Earnings Surge on AI Demand, Stock Jumps After Strong Guidance 
NAB First-Half Earnings Miss Forecasts Amid Rising Global Risks 
Berkshire Hathaway Q1 Earnings Jump 18% as Greg Abel Signals Disciplined Growth Strategy 
GameStop Eyes eBay Acquisition as Stock Prices Surge After Hours 
Pinterest Stock Surges After Strong Q1 2026 Earnings Beat Expectations 
Volvo Car Sales Drop 10% in Early 2026 Despite Growth in Electric Vehicles 
Supermicro Forecasts Strong Q4 Revenue Growth as AI Server Demand Surges 
Middle East Conflict Impacts Australia and New Zealand Businesses 
United Airlines Flight Hits Light Pole During Newark Landing, FAA Investigates 
BUFFALO, N.Y., May 08, 2018 -- Athenex, Inc. (Nasdaq:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that management will present at the Deutsche Bank’s 43rd Annual Health Care Conference in Boston, MA, on Tuesday, May 8th, at 2:10 pm EDT.
The presentation will be webcasted, and can be accessed at the Investor Relations section of the Company’s website, located at www.athenex.com. An archive will be available at this website until August 6, 2018.
About Athenex, Inc.
Founded in 2003, Athenex, Inc. is a global clinical stage biopharmaceutical company dedicated to becoming a leader in the discovery and development of next generation drugs for the treatment of cancer. Athenex is organized around three platforms, including an Oncology Innovation Platform, a Commercial Platform and a Global Supply Chain Platform. Athenex’s Oncology Innovation Platform generates clinical candidates through an extensive understanding of kinases, including novel binding sites and human absorption biology, as well as through the application of Athenex’s proprietary research and selection processes in the lab. The Company’s current clinical pipeline is derived from two different platform technologies Athenex calls Orascovery and Src Kinase Inhibition. The Orascovery platform is based on the novel oral P-glycoprotein pump inhibitor molecule HM30181A, through which Athenex is able to facilitate oral absorption of traditional cytotoxics, which Athenex believes may offer improved patient tolerability and efficacy as compared to IV administration of the same cytotoxics. The Orascovery platform was developed by Hanmi Pharmaceuticals and licensed exclusively to Athenex for all major worldwide territories except Korea, which is retained by Hanmi. The Src Kinase Inhibition platform refers to novel small molecule compounds that have multiple mechanisms of action, including the inhibition of the activity of Src Kinase and the inhibition of tubulin polymerization during cell division. Athenex believes the combination of these mechanisms of action provides a broader range of anti-cancer activity as compared to either mechanism of action alone. Athenex’s employees worldwide are dedicated to improving the lives of cancer patients by creating more active and tolerable treatments. Athenex has offices in Buffalo and Clarence, New York; Cranford, New Jersey; Houston, Texas; Chicago, Illinois; Hong Kong; Taipei, Taiwan and multiple locations in Chongqing, China.
CONTACT:
Jim Polson
Tel: +1-716-427-2952
Athenex, Inc.
